Objective To explore contemporary rates and temporal trends of Guidelines-recommended management options for small renal masses (SRM)<2 cm, that include non-interventional management (NIM), local tumor destruction (LTD) and nephrectomy (either partial –PN– or radical –RN). Methods Within the SEER database (2004-2022), SRM<2 cm patients were identified and stratified according to four examined management options. Estimated annual percentage change (EAPC) were tabulated according to management type. Five-year cancer-specific mortality (CSM) rates were computed. Multivariable logistic regression tested predictors of NIM, LTD and RN. Results Of 20,769 SRM<2 cm patients, 12,107 (58.3%) underwent PN vs 3558 (17.1%) NIM vs 2879 (13.9%) RN vs 2225 (10.7%) LTD. During the study span, NIM rates increased from 8.0% in 2004 to 23.9% in 2022 (EAPC+5.1%, P < .001). The increase in NIM rates was more pronounced in patients aged ≥70 years (from 22.0% to 45.9%, ∆+23.9, EAPC +3.3%, P < .001) and in African American (from 4.5% to 23.2%, ∆+18.7, EAPC +5.0%, P < .001). At multivariable logistic regression models age ≥70 years (OR 9.24, P < .001) and African American race (OR 1.39, P < .001) independently predicted NIM. Five-year CSM remained stable over the study span: 2.8% in 2004 and 2.9% in 2017 (EAPC −1.0%, P = .4). Conclusion In SRM<2 cm patients, rates of NIM are very low, even in the most recent study years. However, NIM rates increased overtime across all sex, age and race categories, with most pronounced increase among elderly and African American. Concurrently, 5-year CSM rates have not increased despite the wider adoption of NIM.
Temporal Trends of Treatment and Mortality in Small Renal Masses <2 cm
Palumbo C.;
2026-01-01
Abstract
Objective To explore contemporary rates and temporal trends of Guidelines-recommended management options for small renal masses (SRM)<2 cm, that include non-interventional management (NIM), local tumor destruction (LTD) and nephrectomy (either partial –PN– or radical –RN). Methods Within the SEER database (2004-2022), SRM<2 cm patients were identified and stratified according to four examined management options. Estimated annual percentage change (EAPC) were tabulated according to management type. Five-year cancer-specific mortality (CSM) rates were computed. Multivariable logistic regression tested predictors of NIM, LTD and RN. Results Of 20,769 SRM<2 cm patients, 12,107 (58.3%) underwent PN vs 3558 (17.1%) NIM vs 2879 (13.9%) RN vs 2225 (10.7%) LTD. During the study span, NIM rates increased from 8.0% in 2004 to 23.9% in 2022 (EAPC+5.1%, P < .001). The increase in NIM rates was more pronounced in patients aged ≥70 years (from 22.0% to 45.9%, ∆+23.9, EAPC +3.3%, P < .001) and in African American (from 4.5% to 23.2%, ∆+18.7, EAPC +5.0%, P < .001). At multivariable logistic regression models age ≥70 years (OR 9.24, P < .001) and African American race (OR 1.39, P < .001) independently predicted NIM. Five-year CSM remained stable over the study span: 2.8% in 2004 and 2.9% in 2017 (EAPC −1.0%, P = .4). Conclusion In SRM<2 cm patients, rates of NIM are very low, even in the most recent study years. However, NIM rates increased overtime across all sex, age and race categories, with most pronounced increase among elderly and African American. Concurrently, 5-year CSM rates have not increased despite the wider adoption of NIM.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


